NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

The decision to block Alzheimer’s ‘wonder’ drugs for use by NHS patients will be appealed against. The two breakthrough drugs ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

THE NHS is failing to keep up with science, experts blasted after breakthrough new dementia drugs were rejected again by the ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. | ITV National News ...

The U.S.-based drugmaker plans to appeal on the grounds that the National Institute for Health and Care Excellence's (NICE) ...